{"id":6727,"date":"2016-04-07T00:00:00","date_gmt":"2016-04-07T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/"},"modified":"2023-06-16T14:34:45","modified_gmt":"2023-06-16T18:34:45","slug":"ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/","title":{"rendered":"Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson&rsquo;s disease"},"content":{"rendered":"<p><strong>Aim<\/strong> \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson&rsquo;s disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT\/SCD) associated with domperidone in the general population. However, the risk in PD is unknown.<\/p>\n<p><strong>Methods <\/strong>\u2014 We conducted a multicentre retrospective cohort study using administrative databases from seven Canadian provinces and the UK Clinical Practice Research Datalink. Using a nested case-control analysis, we estimated the rate ratios (RRs) of VT\/SCD associated with domperidone use compared to no use in patients newly-diagnosed with PD. VT\/SCD events were identified using administrative medical records and vital statistics with a manual review of all potential cases. Meta-analytic methods were used to estimate overall effects across sites.<\/p>\n<p><strong>Results<\/strong> \u2014 Among 214,962 patients with PD, 2,907 cases of VT\/SCD were identified during 886,581 person-years of follow-up (incidence rate 3.28 per 1,000 persons per year. Current use of domperidone was associated with a non-statistically significant 22% increased risk of VT\/SCD (RR 1.22; 95% CI 0.99-1.50) compared with no use. The risk was significantly elevated in those with a history of cardiovascular disease (RR 1.38; 95% CI 1.07-1.78), but not in those without (RR 1.21; 95% CI 0.81-1.81). Dose and duration of use did not affect the magnitude of the risk.<\/p>\n<p><strong>Conclusion<\/strong> \u2014 Domperidone use may increase the risk of VT\/SCD in patients with PD, particularly those with a history of cardiovascular disease. This risk may be underestimated because of imprecision in identifying VT\/SCD events.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson&rsquo;s disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT\/SCD) associated with domperidone in the general population. However, the risk in PD is unknown. Methods \u2014 We conducted a multicentre retrospective [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[41,40,56],"migration-helper-qa-sample-set":[],"class_list":["post-6727","journal_article","type-journal_article","status-publish","hentry","topic-brain-diseases","topic-cardiovascular-disease","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Renoux C, Dell\u2019Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. <em>Br J Clin Pharmacol<\/em>. 2016; 82(2):461-72. Epub 2016 May 19.","source_url":"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12964\/abstract;jsessionid=1BC32CA280020BE2A0D7182AC4430583.f03t04","ices_scientist":[1112,1266,1100,1328],"site":[6733],"research_program":[6740,6746],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"74D1D8A4-8AC6-48F5-82D3-6E97351356B9","sitecore_item_name":"Ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-Parkinsons-Disease","sitecore_field_values":"{\r\n  \"Title\": \"Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease\",\r\n  \"Short title\": \"Ventricular tachyarrhythmia and sudden\",\r\n  \"Summary\": \"The study found that domperidone use may increase the risk of ventricular tachyarrhythmia and sudden cardiac death in patients with Parkinson's Disease.\",\r\n  \"Citation\": \"<p>Renoux C, Dell&rsquo;Aniello S, Khairy P, Marras C, Bugden S, Turin TC, Blais L, Tamim H, Evans C, Steele R, Dormuth C, Ernst P; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. <em>Br J Clin Pharmacol<\/em>. 2016; 82(2):461-72. Epub 2016 May 19.<\/p>\",\r\n  \"Abstract\": \"<p><strong>Aim<\/strong> &mdash; Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised regarding an increased risk of ventricular tachyarrhythmia and sudden cardiac death (VT\/SCD) associated with domperidone in the general population. However, the risk in PD is unknown.<\/p>rn<p><strong>Methods <\/strong>&mdash; We conducted a multicentre retrospective cohort study using administrative databases from seven Canadian provinces and the UK Clinical Practice Research Datalink. Using a nested case-control analysis, we estimated the rate ratios (RRs) of VT\/SCD associated with domperidone use compared to no use in patients newly-diagnosed with PD. VT\/SCD events were identified using administrative medical records and vital statistics with a manual review of all potential cases. Meta-analytic methods were used to estimate overall effects across sites.<\/p>rn<p><strong>Results<\/strong> &mdash; Among 214,962 patients with PD, 2,907 cases of VT\/SCD were identified during 886,581 person-years of follow-up (incidence rate 3.28 per 1,000 persons per year. Current use of domperidone was associated with a non-statistically significant 22% increased risk of VT\/SCD (RR 1.22; 95% CI 0.99-1.50) compared with no use. The risk was significantly elevated in those with a history of cardiovascular disease (RR 1.38; 95% CI 1.07-1.78), but not in those without (RR 1.21; 95% CI 0.81-1.81). Dose and duration of use did not affect the magnitude of the risk.<\/p>rn<p><strong>Conclusion<\/strong> &mdash; Domperidone use may increase the risk of VT\/SCD in patients with PD, particularly those with a history of cardiovascular disease. This risk may be underestimated because of imprecision in identifying VT\/SCD events.<\/p>rn<p><a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12964\/abstract;jsessionid=1BC32CA280020BE2A0D7182AC4430583.f03t04\" title=\"Opens to HTML full text in a new window\" target=\"_blank\">View full text<\/a><\/p>\",\r\n  \"Keywords\": \"{EDACCF0C-A0D0-4496-9216-D3055A23BC38}|{0D3BD683-F179-40A8-924F-D7895622D238}|{92E2791D-5DAB-4244-8A85-434D524D9A12}|{A5F436B7-3935-4915-ABFB-160DCA0AB95E}\",\r\n  \"Research Programs\": \"{46DF28D2-EDE8-4DF2-8CC0-87CEF464E435}|{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}\",\r\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\r\n  \"ICES Scientists\": \"{44B77033-DFD5-40B7-9825-46526C4A6DA6}|{242795DE-E521-4AAA-A4DF-93AF84CC17CA}|{4A1034A0-5248-46A2-805E-20FBC57B1237}|{6B7BCAA7-8CF8-4655-81FD-CB55616742F5}\",\r\n  \"Posted Date\": \"20160407T000000\",\r\n  \"Show on Publications Landing Page\": \"1\"\r\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2016\/January\/Ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-Parkinsons-Disease"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson&#039;s disease<\/title>\n<meta name=\"description\" content=\"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson&#039;s disease (PD). Concerns have been raised\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson&#039;s disease\" \/>\n<meta property=\"og:description\" content=\"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson&#039;s disease (PD). Concerns have been raised\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T18:34:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\\\/\",\"name\":\"ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2016-04-07T04:00:00+00:00\",\"dateModified\":\"2023-06-16T18:34:45+00:00\",\"description\":\"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease","description":"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease","og_description":"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-16T18:34:45+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/","name":"ICES | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2016-04-07T04:00:00+00:00","dateModified":"2023-06-16T18:34:45+00:00","description":"Aim \u2014 Domperidone is preferentially used over other antiemetic agents to treat digestive symptoms in Parkinson's disease (PD). Concerns have been raised","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/ventricular-tachyarrhythmia-and-sudden-cardiac-death-with-domperidone-use-in-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/6727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6740"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1328"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1100"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1266"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1112"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=6727"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=6727"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=6727"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=6727"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=6727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}